An editorial suggests that kallikrein inhibition with lanadelumab given by fortnightly subcutaneous injection would be convenient and widely accessible. It adds that early safety indications are encouraging, with no indication of antibody formation or the anaphylactoid events associated with short-term inhibition of kallikrein; therefore, self-administration could be feasible. It adds that if these preliminary findings “prove reproducible in larger studies currently underway, and if the treatment will be affordable, lanadelumab could herald a transformation in the way that we manage hereditary angioedema and in the life prospects for families affected by this devastating disorder.”